Category : Search result: Chandigarh pharma


Odisha Approves Pharma & Medtech Policy 2025

Odisha's new Pharma & Medtech Policy 2025 aims to make the state a strategic hub for healthcare manufacturing. The policy includes plans for dedicated industrial parks and a roadmap aligned with India's 2047 vision. Read more.

Granules India's US facility passes FDA GMP inspection

Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.

Chandigarh Headlines: Major Updates You Need to Know

Stay ahead with the latest from Chandigarh! Get crucial updates on civic matters, traffic alerts, weather, and key political developments for December 3, 2025. Watch the full video for details.

Sun Pharma's Ilumya for Psoriasis Launched in India

Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.

Chandigarh to Develop 25 Acres of Reclaimed Land

Chandigarh Administration plans residential, commercial facilities and school on 25 acres of reclaimed land from Dadumajra landfill site. Major urban development initiative underway.

India's Bulk Drug Makers Ramp Up CDMO Investments

Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.

Page 1 of 4